Edith B.
- Country
- France
- Department
- Medical oncology
Research Overview
- Phase I/II Study of TG4050 in Patients with Stage III/IV HPV-Negative Squamous-Cell Carcinoma of the Head and Neck Post-Surgery and Adjuvant Therapy
- Evaluation of Petosemtamab Monotherapy and Combination Therapy in Advanced Metastatic Colorectal Cancer and Malignant Solid Tumors
- Evaluation of TG4001 and Avelumab in HPV-16 Positive Recurrent or Metastatic Malignancies: A Phase Ib/II Clinical Trial
Data & Insights
Has run more than one trial at 154 of 308 partner sites.
Specializations
Thoracic Oncology
Clinical research in non-small cell lung cancer and small cell lung cancer, with attention to advanced, metastatic, recurrent, and first-line treatment settings, including biomarker-defined disease such as KRAS G12C-mutated and PD-L1-positive tumours.
- Advanced and metastatic non-small cell lung cancer
- Small cell lung cancer
- KRAS G12C-mutated lung cancer
- PD-L1-selected thoracic malignancies
Therapeutic interest includes immunotherapy, targeted treatment combinations, and novel antitumour strategies for resistant or high-risk lung cancer.
Head and Neck Cancer and Squamous Cell Carcinoma
Research activity covers head and neck squamous cell carcinoma across recurrent, metastatic, and previously treated disease, with a focus on PD-L1-positive populations and treatment options after anti-PD-1 exposure.
- Recurrent or metastatic head and neck squamous cell carcinoma
- Incurable metastatic/recurrent HNSCC
- PD-L1-positive squamous tumours
- Post-PD-1 treatment disease
The therapeutic landscape includes immune checkpoint blockade, antibody-based combinations, and approaches aimed at improving survival in advanced squamous malignancies.
Breast Cancer and HER2-Driven Disease
Clinical interest includes ER+/HER2- early breast cancer and HER2-positive breast cancer, with activity in both early-stage recurrence prevention and advanced disease with central nervous system involvement.
- ER+/HER2- early breast cancer
- HER2-positive breast cancer
- Locally advanced or metastatic breast cancer
- HER2-aberrant solid tumours
Therapeutic focus extends to endocrine-based strategies, HER2-targeted therapy, and combination regimens designed to reduce recurrence and control advanced disease.
Central Nervous System Tumours and Pediatric Oncology
Research involvement spans glioma, high-grade glioma, medulloblastoma, and pediatric low-grade glioma, with attention to both newly diagnosed and recurrent settings.
- Glioma and high-grade glioma
- Medulloblastoma
- Pediatric low-grade glioma
- Brain tumours with molecular risk features
The therapeutic emphasis includes targeted agents, immunotherapy, and treatment adaptation for molecularly defined paediatric and adult brain tumours.
Rare Solid Tumours and Precision Oncology
Work also extends to advanced solid tumours and selected rare cancers, including metastatic leiomyosarcoma, uveal melanoma, pancreatic ductal adenocarcinoma, and tumours with HER2 aberrations or other actionable alterations.
- Metastatic leiomyosarcoma
- Uveal melanoma
- Pancreatic ductal adenocarcinoma
- Advanced solid tumours with molecular targets
Therapeutic interest is centred on precision oncology, novel antibody-drug combinations, and mutation-directed treatment options across refractory solid tumours.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.